Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

SAN DIEGO, Nov. 3, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company's financial results for the quarter ended September 30, 2011.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Optimer reported total revenues for the third quarter of 2011 of $11.1 million, compared $669,000 for the third quarter in 2010. This includes net product sales of $10.6 million recognized from the sale of DIFICID™. Optimer recognizes product sales of DIFICID upon delivery of product to its wholesalers.

  • For the quarter ended September 30, 2011, the $10.6 million in net sales to wholesalers reflected a total of 4,335 DIFICID treatments
  • 2,505 DIFICID treatments were shipped from wholesalers to hospitals, retail pharmacies and long-term care facilities in the quarter ended September 30, 2011
  • 535 hospitals had ordered DIFICID as of September 30, 2011
  • 304 hospitals had placed DIFICID on formulary, and 346 hospital formulary reviews were pending as of October 21, 2011.

  • "In only a few months since our first DIFICID sale on July 19th we've seen significant interest in DIFICID converting into uptake and adoption. We reported $10.6 million in sales to our wholesalers in the third quarter, and we expect continued strong uptake as the launch progresses," said Pedro Lichtinger, President and CEO of Optimer. "This confirms our belief that DIFICID meets the need for a Clostridium difficile-associated diarrhea treatment addressing the problem of recurrence by providing a sustained clinical response. As the medical community becomes more familiar with and recognizes the value of DIFICID, we anticipate that adoption will continue."Optimer reported a net loss for the third quarter of 2011 of $26.4 million, or ($0.57) 
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
    2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
    3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
    4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
    5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
    6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
    7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
    8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
    9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
    10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
    11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Pipette.com announces their Holiday in ... submit their #HolidayInTheLab pictures for a chance to win ... For those struggling to think of a holiday gift ... the Lab Contest provides the ideal holiday presents. The ... send pictures of their chemistree, holiday sweaters, as well ...
    (Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
    (Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
    (Date:12/22/2014)... Fertility Associates of Memphis has announced ... , a network of more than 20 contributing ... have fast access to a national pool of frozen ... Fertility Associates of Memphis is the only fertility clinic ... , Dr. William Kutteh , director of Fertility ...
    Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
    ... , , , BEIJING , Feb. 8 ... in-vitro,diagnostic ("IVD") company, today announced that it will participate at the,following investor conferences in March 2010 : ... Location, ... Hotel, China Investment ...
    ... , NEW YORK , Feb. 8 ... relations and corporate communications for domestic and international clients, announced ... have joined as Managing Directors. , “Lisa and ... serve our clients well,” said Lynn Morgen , co-founder ...
    ... , , , , ... 3SBio Inc. (Nasdaq:, SSRX ) ("3SBio" or "the Company"), ... developing, manufacturing and marketing,biopharmaceutical products, today announced a collaboration ... commercialize its,Nephoxil(R) pharmaceutical product for the treatment of hyperphosphatemia ...
    Cached Biology Technology:China Medical Technologies to Participate Investor Conferences in March 2010 2MBS Value Partners Hires Two New Senior Staff Members 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 33SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 4
    (Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems ... http://photos.prnewswire.com/prnh/20130307/600769 The North American ... CAGR of 3.6% from 2014 to 2019. Although the ... Canada is expected to grow ...
    (Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
    (Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
    Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
    ... infected with human immunodeficiency virus (HIV), highly active ... of Kaposi sarcoma and non-Hodgkin lymphoma, according to ... of the Journal of the National Cancer Institute. ... (AIDS) have reported increased risks of several cancers, ...
    ... short pulses is a promising, non-invasive procedure for ... healthy tissue, according to a study in the ... focused ultrasound (HIFU) is more powerful than standard ... continuous exposures that raise the temperature inside cancerous ...
    ... the NIH new policy from yesterday : ... rule on Enhanced Public Access to NIH Research Information ... opportunity to take advantage of available technology and existing ... not-for-profit medical and scientific publishers. The final rule ignores ...
    Cached Biology News:Antiretroviral therapy may prevent excess risk of some cancers in people with HIV 2Pulsating ultrasound enhances gene therapy for tumors 2Not-for-profit publishers call NIH public access rule a missed opportunity 2Not-for-profit publishers call NIH public access rule a missed opportunity 3
    Request Info...
    ... The Zero Blunt ... for Sequencing is designed ... sequencing of blunt-end PCR ... provides 5-minute TOPO Cloning ...
    ... 1 kit. Convenient way to ... Conjugations are carried out under mild conditions ... Dyes are packaged in premeasured amounts and ... Category: Blotting & Labeling & Detection, Protein ...
    ...
    Biology Products: